• About
• Links
• Contact
• Sitemap
• 

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Summary

The report provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and strengths, weaknesses, opportunities and threats facing these companies. Its scope includes

Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.

Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.

Analysis of the competitive positioning of the top 10 biotechnology companies globally.

Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders, autoimmune disorders, and product classes.

Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.

SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.

Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.

Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors.

Effectively plan your investment strategies by identifying companies with maximum investment potential.

Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

Table of Contents

1 Table of Contents 4

• 1.1 List of Tables 9
• 1.2 List of Figures 12

2 Introduction 15

• 2.1 Report Guidance 16

3 Global Biotechnology Industry – Market Characterization 17

• 3.1 Global Biotechnology Industry – Market Size 17
• 3.2 Top 10 Companies – Market Forecast 18
• 3.3 Therapeutic Focus of the Biotechnology Industry 20
• 3.4 Global Biotechnology Industry – Growth Drivers and Restraints 22
  • 3.4.1 Growth Drivers 22
  • 3.4.2 Restraints 23

4 Top 10 Biotechnology Companies – Competitive Landscape 24

• 4.1 Competitive Landscape Framework 24
• 4.2 Financial Benchmarking 25
  • 4.2.1 Earnings per Share 26
  • 4.2.2 Net Profit Margin 26
  • 4.2.3 Current Ratio 27
  • 4.2.4 Debt to Equity ratio 27
  • 4.2.5 Asset Turnover Ratio 28
• 4.3 R&D Productivity Framework 28

5 Global Biotechnology Industry – Strategic Consolidations 30

• 5.1 Pharma Biotech Space – Deals Analysis (2008) 30
• 5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry 31

6 Top 10 Biotechnology Companies – Amgen 33

• 6.1 Company Overview 33
  • 6.1.1 Introduction 33
  • 6.1.2 Business Description 33
• 6.2 Strategic Positioning 34
  • 6.2.1 SWOT Analysis 34
• 6.3 Financial Analysis 36
  • 6.3.1 Revenue Analysis and Forecasts 36
  • 6.3.2 Ratio Analysis 39
  • 6.3.3 DuPont Analysis 43
• 6.4 Marketed Products 44
  • 6.4.1 Key Marketed Products 44
• 6.5 R&D Strategies 45
  • 6.5.1 Therapeutic Focus 45
  • 6.5.2 R&D Productivity 46
• 6.6 Product Pipeline 47
  • 6.6.1 Overview 47
  • 6.6.2 Key Pipeline Products 48
• 6.7 Licensing Agreements 49
  • 6.7.1 Overview 49

7 Top 10 Biotechnology Companies – Genentech (Roche) 50

• 7.1 Company Overview 50
  • 7.1.1 Introduction 50
  • 7.1.2 Business Description 50
• 7.2 Strategic Positioning 51
  • 7.2.1 SWOT Analysis 51
• 7.3 Financial Analysis 52
  • 7.3.1 Revenue Analysis and Forecasts 52
  • 7.3.2 Ratio Analysis 55
  • 7.3.3 DuPont Analysis 59
• 7.4 Marketed Products 60
  • 7.4.1 Key Marketed Products 60
• 7.5 R&D Strategies 61
  • 7.5.1 Therapeutic Focus 61
  • 7.5.2 R&D Productivity 61
• 7.6 Product Pipeline 62
  • 7.6.1 Overview 62
  • 7.6.2 Key Pipeline Products 64
• 7.7 Licensing Agreements 64
  • 7.7.1 Overview 64

8 Top 10 Biotechnology Companies – Gilead Sciences 66

• 8.1 Company Overview 66
  • 8.1.1 Introduction 66
  • 8.1.2 Business Description 66
• 8.2 Strategic Positioning 67
  • 8.2.1 SWOT Analysis 67
• 8.3 Financial Analysis 68
  • 8.3.1 Revenue Analysis and Forecasts 68
  • 8.3.2 Ratio Analysis 71
  • 8.3.3 DuPont Analysis 75
• 8.4 Marketed Products 76
  • 8.4.1 Key Marketed Products 76
• 8.5 R&D Strategies 76
  • 8.5.1 Therapeutic Focus 76
  • 8.5.2 R&D Productivity 77
• 8.6 Product Pipeline 78
  • 8.6.1 Overview 78
  • 8.6.2 Key Pipeline Products 79
• 8.7 Licensing Agreements 79
  • 8.7.1 Overview 79

9 Top 10 Biotechnology Companies – UCB Pharma 80

• 9.1 Company Overview 80
  • 9.1.1 Introduction 80
  • 9.1.2 Business Description 80
• 9.2 Strategic Positioning 81
  • 9.2.1 SWOT Analysis 81
• 9.3 Financial Analysis 82
  • 9.3.1 Revenue Analysis and Forecasts 82
  • 9.3.2 Ratio Analysis 85
  • 9.3.3 DuPont Analysis 89
• 9.4 Marketed Products 90
  • 9.4.1 Key Marketed Products 90
• 9.5 R&D Strategies 90
  • 9.5.1 Therapeutic Focus 90
  • 9.5.2 R&D Productivity 90
• 9.6 Product Pipeline 92
  • 9.6.1 Overview 92
  • 9.6.2 Key Pipeline Products 93
• 9.7 Licensing Agreements 93
  • 9.7.1 Overview 93

10 Top 10 Biotechnology Companies – Genzyme 94

• 10.1 Company Overview 94
  • 10.1.1 Introduction 94
  • 10.1.2 Business Description 94
• 10.2 Strategic Positioning 95
  • 10.2.1 SWOT Analysis 95
• 10.3 Financial Analysis 97
  • 10.3.1 Revenue Analysis and Forecasts 97
  • 10.3.2 Ratio Analysis 99
  • 10.3.3 DuPont Analysis 102
• 10.4 Marketed Products 103
  • 10.4.1 Key Marketed Products 103
• 10.5 R&D Strategies 104
  • 10.5.1 Therapeutic Focus 104
  • 10.5.2 R&D Productivity 105
• 10.6 Product Pipeline 106
  • 10.6.1 Overview 106
  • 10.6.2 Key Pipeline Products 107
• 10.7 Licensing Agreements 107
  • 10.7.1 Overview 107

11 Top 10 Biotechnology Companies – Biogen Idec 109

• 11.1 Company Overview 109
  • 11.1.1 Introduction 109
  • 11.1.2 Business Description 109
• 11.2 Strategic Positioning 110
  • 11.2.1 SWOT Analysis 110
• 11.3 Financial Analysis 111
  • 11.3.1 Revenue Analysis and Forecasts 111
  • 11.3.2 Ratio Analysis 114
  • 11.3.3 DuPont Analysis 118
• 11.4 Marketed Products 119
  • 11.4.1 Key Marketed Products 119
• 11.5 R&D Strategies 119
  • 11.5.1 Therapeutic Focus 119
  • 11.5.2 R&D Productivity 120
• 11.6 Product Pipeline 121
  • 11.6.1 Overview 121
  • 11.6.2 Key Pipeline Products 122
• 11.7 Licensing Agreements 122
  • 11.7.1 Overview 122

12 Top 10 Biotechnology Companies – CSL Limited 123

• 12.1 Company Overview 123
  • 12.1.1 Introduction 123
  • 12.1.2 Business Description 123
• 12.2 Strategic Positioning 124
  • 12.2.1 SWOT Analysis 124
• 12.3 Financial Analysis 125
  • 12.3.1 Revenue Analysis and Forecasts 125
  • 12.3.2 Ratio Analysis 128
  • 12.3.3 DuPont Analysis 132
• 12.4 Marketed Products 133
  • 12.4.1 Key Marketed Products 133
• 12.5 R&D Strategies 133
  • 12.5.1 Therapeutic Focus 133
  • 12.5.2 R&D Productivity 134
• 12.6 Product Pipeline 135
  • 12.6.1 Overview 135
  • 12.6.2 Key Pipeline Products 135
• 12.7 Licensing Agreements 136
  • 12.7.1 Overview 136

13 Top 10 Biotechnology Companies – Celgene 137

• 13.1 Company Overview 137
  • 13.1.1 Introduction 137
  • 13.1.2 Business Description 137
• 13.2 Strategic Positioning 138
  • 13.2.1 SWOT Analysis 138
• 13.3 Financial Analysis 139
  • 13.3.1 Revenue Analysis and Forecasts 139
  • 13.3.2 Ratio Analysis 141
  • 13.3.3 DuPont Analysis 144
• 13.4 Marketed Products 145
  • 13.4.1 Key Marketed Products 145
• 13.5 R&D Strategies 146
  • 13.5.1 Therapeutic Focus 146
  • 13.5.2 R&D Productivity 146
• 13.6 Product Pipeline 148
  • 13.6.1 Overview 148
  • 13.6.2 Key Pipeline Products 149
• 13.7 Licensing Agreements 149
  • 13.7.1 Overview 149

14 Top 10 Biotechnology Companies – Cephalon 150

• 14.1 Company Overview 150
  • 14.1.1 Introduction 150
  • 14.1.2 Business Description 150
• 14.2 Strategic Positioning 151
  • 14.2.1 SWOT Analysis 151
• 14.3 Financial Analysis 152
  • 14.3.1 Revenue Analysis and Forecasts 152
  • 14.3.2 Ratio Analysis 154
  • 14.3.3 DuPont Analysis 158
• 14.4 Marketed Products 158
  • 14.4.1 Key Marketed Products 158
• 14.5 R&D Strategies 159
  • 14.5.1 Therapeutic Focus 159
  • 14.5.2 R&D Productivity 159
• 14.6 Product Pipeline 161
  • 14.6.1 Overview 161
  • 14.6.2 Key Pipeline Products 162
• 14.7 Licensing Agreements 162
  • 14.7.1 Overview 162

15 Top 10 Biotechnology Companies – Actelion 163

• 15.1 Company Overview 163
  • 15.1.1 Introduction 163
  • 15.1.2 Business Description 163
• 15.2 Strategic Positioning 164
  • 15.2.1 SWOT Analysis 164
• 15.3 Financial Analysis 165
  • 15.3.1 Revenue Analysis and Forecasts 165
  • 15.3.2 Ratio Analysis 166
  • 15.3.3 DuPont Analysis 171
• 15.4 Marketed Products 172
  • 15.4.1 Key Marketed Products 172
• 15.5 R&D Strategies 172
  • 15.5.1 Therapeutic Focus 172
  • 15.5.2 R&D Productivity 172
• 15.6 Product Pipeline 174
  • 15.6.1 Overview 174
  • 15.6.2 Key Pipeline Products 174
• 15.7 Licensing Agreements 175
  • 15.7.1 Overview 175

16 Top 10 Biotechnology Companies – Appendix 176

• 16.1 Market Definitions 176
• 16.2 Abbreviations 178
• 16.3 Research Methodology 178
  • 16.3.1 Coverage 179
  • 16.3.2 Secondary Research 179
  • 16.3.3 Primary Research 180
  • 16.3.4 Expert Panel Validation 180
• 16.4 Contact Us 180
• 16.5 Disclaimer 180
• 16.6 Sources 181

1.1 List of Tables

• Table 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008 17
• Table 2: Global, Top 25 Biologic Drugs by Annual Sales. 2008 18
• Table 3: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012 19
• Table 4: Top 10 Biotechnology Companies, Global, Company Rankings, 2008-2012 20
• Table 5: Top 10 Biotechnology Companies, Global, Rankings by Strength of Marketed and Pipeline Products, 2008 25
• Table 6: Top 10 Biotechnology Companies, Global, Earnings per Share, ($), 2008 26
• Table 7: Top 10 Biotechnology Companies, Global, Net Profit Margin, (%), 2008 26
• Table 8: Top 10 Biotechnology Companies, Global, Current Ratio, 2008 27
• Table 9: Top 10 Biotechnology Companies, Global, Debt to Equity Ratio, 2008 27
• Table 10: Top 10 Biotechnology Companies, Global, Asset Turnover Ratio, 2008 28
• Table 11: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (1), 2008 29
• Table 12: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (2), 2008 29
• Table 13: Biotechnology Industry, Global, Key M&A Deals in 2008 30
• Table 14: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014 31
• Table 15: Amgen Inc., Historical Revenue, ($m), 2004-2008 37
• Table 16: Amgen Inc., Revenue Forecast, ($m), 2008-2012 37
• Table 17: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008 38
• Table 18: Equity Ratios for Amgen Inc., ($), 2004-2008 39
• Table 19: Profitability Ratios for Amgen Inc., (%), 2004-2008 40
• Table 20: Liquidity Ratios for Amgen Inc., 2004-2008 41
• Table 21: Leverage Ratios for Amgen Inc., 2004-2008 42
• Table 22: Efficiency Ratios for Amgen Inc., 2004-2008 42
• Table 23: Expenditure on R&D for Amgen Inc., ($m), 2004-2008 46
• Table 24: Phase-wise Analysis of Amgen R&D Pipeline, 2009 47
• Table 25: Amgen Inc., Licensing Agreements for Drugs, 2008-July 2009 49
• Table 26: Genentech, Historical Revenue, ($m), 2004-2008 53
• Table 27: Genentech, Revenue Forecast, ($m), 2008-2012 53
• Table 28: Genentech, Net Income and R&D Expense, ($m), 2004-2008 54
• Table 29: Equity Ratios for Genentech, ($), 2004-2008 55
• Table 30: Profitability Ratios for Genentech, (%), 2004-2008 56
• Table 31: Liquidity Ratios for Genentech, 2004-2008 57
• Table 32: Leverage Ratios for Genentech, 2004-2008 58
• Table 33: Efficiency Ratios for Genentech, 2004-2008 59
• Table 34: Expenditure on R&D for Genentech, ($m), 2004-2008 62
• Table 35: Phase-wise Analysis of Genentech R&D Pipeline, 2009 62
• Table 36: Genentech, Licensing Agreements for Drugs, 2008-July 2009 65
• Table 37: Gilead, Historical Revenue, ($m), 2004-2008 69
• Table 38: Gilead, Revenue Forecast, ($m), 2008-2012 69
• Table 39: Gilead, Net Income and R&D Expense, ($m), 2004-2008 70
• Table 40: Equity Ratios for Gilead, ($), 2004-2008 71
• Table 41: Profitability Ratios for Gilead, (%), 2004-2008 72
• Table 42: Liquidity Ratios for Gilead, 2004-2008 73
• Table 43: Leverage Ratios for Gilead, 2004-2008 74
• Table 44: Efficiency Ratios for Gilead, 2004-2008 74
• Table 45: Expenditure on R&D by Gilead, ($m), 2004-2008 77
• Table 46: Phase-wise Analysis of Gilead R&D Pipeline, 2009 78
• Table 47: Gilead, Licensing Agreements for Drugs, 2008-July 2009 79
• Table 48: UCB Pharma, Historical Revenue, ($m), 2004-2008 83
• Table 49: UCB Pharma, Revenue Forecast, ($m), 2008-2012 83
• Table 50: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008 84
• Table 51: Equity Ratios for UCB Pharma, ($), 2004-2008 85
• Table 52: Profitability Ratios for UCB Pharma, (%), 2004-2008 86
• Table 53: Liquidity Ratios for UCB Pharma, 2004-2008 87
• Table 54: Leverage Ratios for UCB Pharma, 2004-2008 88
• Table 55: Efficiency Ratios for UCB Pharma, 2004-2008 88
• Table 56: Expenditure on R&D by UCB Pharma, ($m), 2004-2008 91
• Table 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009 92
• Table 58: UCB Pharma, Licensing Agreements for Drugs, 2008-July 2009 93
• Table 59: Genzyme, Historical Revenue, ($m), 2004-2008 97
• Table 60: Genzyme, Revenue Forecast, ($m), 2008-2012 98
• Table 61: Genzyme, Net Income and R&D Expense, ($m), 2004-2008 98
• Table 62: Equity Ratios for Genzyme, ($), 2004-2008 99
• Table 63: Profitability Ratios for Genzyme, (%), 2004-2008 100
• Table 64: Liquidity Ratios for Genzyme, 2004-2008 101
• Table 65: Leverage Ratios for Genzyme, 2004-2008 102
• Table 66: Efficiency Ratios for Genzyme, 2004-2008 102
• Table 67: Expenditure on R&D by Genzyme, ($m), 2004-2008 105
• Table 68: Phase-wise Analysis of Genzyme R&D Pipeline, 2009 106
• Table 69: Genzyme, Licensing Agreements for Drugs, 2008-July 2009 107
• Table 70: Biogen Idec, Historical Revenue, ($m), 2004-2008 112
• Table 71: Biogen Idec, Revenue Forecast, ($m), 2008-2012 112
• Table 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008 113
• Table 73: Equity Ratios for Biogen Idec, ($), 2004-2008 114
• Table 74: Profitability Ratios for Biogen Idec, (%), 2004-2008 115
• Table 75: Liquidity Ratios for Biogen Idec, 2004-2008 116
• Table 76: Leverage Ratios for Biogen Idec, 2004-2008 117
• Table 77: Efficiency Ratios for Biogen Idec, 2004-2008 117
• Table 78: Expenditure on R&D for Biogen Idec, ($m), 2004-2008 120
• Table 79: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009 121
• Table 80: Biogen Idec, Licensing Agreements for Drugs, 2008-July 2009 122
• Table 81: CSL Limited, Historical Revenue, ($m), 2005-2009 126
• Table 82: CSL Limited, Revenue Forecast, ($m), 2009-2013 126
• Table 83: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009 127
• Table 84: Equity Ratios for CSL Limited, ($), 2005-2009 128
• Table 85: Profitability Ratios for CSL Limited, (%), 2005-2009 129
• Table 86: Liquidity Ratios for CSL Limited, 2005-2009 130
• Table 87: Leverage Ratios for CSL Limited, 2005-2009 131
• Table 88: Efficiency Ratios for CSL Limited, 2005-2009 131
• Table 89: Expenditure on R&D by CSL Limited, ($m), 2005-2009 134
• Table 90: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009 135
• Table 91: CSL Limited, Licensing Agreements for Drugs, 2008-July 2009 136
• Table 92: Celgene, Historical Revenue, ($m), 2004-2008 140
• Table 93: Celgene, Revenue Forecast, ($m), 2008-2012 140
• Table 94: Celgene, Net Income and R&D Expense, ($m), 2004-2008 141
• Table 95: Equity Ratios for Celgene, ($), 2004-2008 142
• Table 96: Profitability Ratios for Celgene, (%), 2004-2008 143
• Table 97: Liquidity Ratios for Celgene, 2004-2008 143
• Table 98: Leverage Ratios for Celgene, 2004-2008 144
• Table 99: Efficiency Ratios for Celgene, 2004-2008 144
• Table 100: Expenditure on R&D by Celgene, ($m), 2004-2008 147
• Table 101: Phase-wise Analysis of Celgene R&D Pipeline, 2009 148
• Table 102: Celgene, Licensing Agreements for Drugs, 2008-July 2009 149
• Table 103: Cephalon, Historical Revenue, ($m), 2004-2008 153
• Table 104: Cephalon, Revenue Forecast, ($m), 2008-2012 153
• Table 105: Cephalon, Net Income and R&D Expense, ($m), 2004-2008 154
• Table 106: Equity Ratios for Cephalon, ($), 2004-2008 155
• Table 107: Profitability Ratios for Cephalon, (%), 2004-2008 156
• Table 108: Liquidity Ratios for Cephalon, 2004-2008 156
• Table 109: Leverage Ratios for Cephalon, 2004-2008 157
• Table 110: Efficiency Ratios for Cephalon, 2004-2008 157
• Table 111: Expenditure on R&D for Cephalon, ($m), 2004-2008 160
• Table 112: Phase-wise Analysis of Cephalon R&D Pipeline, 2009 161
• Table 113: Cephalon, Licensing Agreements for Drugs, 2008-July 2009 162
• Table 114: Actelion, Historical Revenue, ($m), 2004-2008 166
• Table 115: Actelion, Revenue Forecast, ($m), 2008-2012 166
• Table 116: Actelion, Net Income and R&D Expense, ($m), 2004-2008 166
• Table 117: Equity Ratios for Actelion, ($), 2004-2008 167
• Table 118: Profitability Ratios for Actelion, (%), 2004-2008 168
• Table 119: Liquidity Ratios for Actelion, 2004-2008 169
• Table 120: Leverage Ratios for Actelion, 2004-2008 170
• Table 121: Efficiency Ratios for Actelion, 2004-2008 170
• Table 122: Expenditure on R&D by Actelion, ($m), 2004-2008 173
• Table 123: Phase-wise Analysis of Actelion R&D Pipeline, 2009 174
• Table 124: Actelion, Licensing Agreements for Drugs, 2008-July 2009 175

1.2 List of Figures

• Figure 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008 17
• Figure 2: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012 19
• Figure 3: Global, Biotech Pipeline Drugs by Therapy Areas, (%), 2008 20
• Figure 4: Global, Biotech Pipeline Drugs by Product Classes, 2008 21
• Figure 5: Biotechnology Industry, Global, Growth Drivers and Restraints,2008 22
• Figure 6: Top 10 Biotechnology Companies, Global, Competitive Positioning, 2008 24
• Figure 7: Top 10 Biotechnology Companies, Global, Competitive Landscape Framework, 2008 25
• Figure 8: Top 10 Biotechnology Companies, Global, R&D Productivity Framework, 2008 28
• Figure 9: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014 31
• Figure 10: SWOT Analysis of Amgen Inc. 34
• Figure 11: Amgen Inc., Annual Revenue Forecasts, ($m), 2004-2012 37
• Figure 12: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008 38
• Figure 13: Amgen Inc., Earnings per Share, ($), 2004-2008 39
• Figure 14: Amgen Inc., Net Profit Margin, (%), 2004-2008 40
• Figure 15: Amgen Inc., Current Ratio, 2004-2008 41
• Figure 16: Amgen Inc., Debt to Equity Ratio, 2004-2008 42
• Figure 17: Amgen Inc., Return on Equity, (%), 2004-2008 43
• Figure 18: DuPont Analysis for Amgen Inc., 2004-2008 43
• Figure 19: Therapeutic Focus of Amgen R&D Pipeline, 2009 45
• Figure 20: R&D Productivity for Amgen Inc., 2004-2008 46
• Figure 21: Phase-wise Analysis of Amgen R&D Pipeline, 2009 47
• Figure 22: SWOT Analysis of Genentech 51
• Figure 23: Genentech, Annual Revenue Forecasts, ($m), 2004-2012 53
• Figure 24: Genentech, Net Income and R&D Expense, ($m), 2004-2008 54
• Figure 25: Genentech, Earnings per Share, ($), 2004-2008 55
• Figure 26: Genentech, Net Profit Margin, (%), 2004-2008 56
• Figure 27: Genentech, Current Ratio, 2004-2008 57
• Figure 28: Genentech, Debt to Equity Ratio, 2004-2008 58
• Figure 29: Genentech, Return on Equity, (%), 2004-2008 59
• Figure 30: DuPont Analysis for Genentech, 2004-2008 60
• Figure 31: Therapeutic Focus of Genentech R&D Pipeline, 2009 61
• Figure 32: R&D Productivity for Genentech, 2004-2008 61
• Figure 33: Phase-wise Analysis of Genentech R&D Pipeline, 2009 62
• Figure 34: SWOT Analysis of Gilead 67
• Figure 35: Gilead, Annual Revenue Forecasts, ($m), 2004-2012 69
• Figure 36: Gilead, Net Income and R&D Expense, ($m), 2004-2008 70
• Figure 37: Gilead, Earnings per Share, ($), 2004-2008 71
• Figure 38: Gilead, Net Profit Margin, (%), 2004-2008 72
• Figure 39: Gilead, Current Ratio, 2004-2008 73
• Figure 40: Gilead, Debt to Equity Ratio, 2004-2008 74
• Figure 41: Gilead, Return on Equity, (%), 2004-2008 75
• Figure 42: DuPont Analysis for Gilead, 2004-2008 75
• Figure 43: Therapeutic Focus of Gilead R&D Pipeline, 2009 76
• Figure 44: R&D Productivity for Gilead, 2004-2008 77
• Figure 45: Phase-wise Analysis of Gilead R&D Pipeline, 2009 78
• Figure 46: SWOT Analysis of UCB Pharma 81
• Figure 47: UCB Pharma, Annual Revenue Forecasts, ($m), 2004-2012 83
• Figure 48: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008 84
• Figure 49: UCB Pharma, Earnings per Share, ($), 2004-2008 85
• Figure 50: UCB Pharma, Net Profit Margin, (%), 2004-2008 86
• Figure 51: UCB Pharma, Current Ratio, 2004-2008 87
• Figure 52: UCB Pharma, Debt to Equity Ratio, 2004-2008 88
• Figure 53: UCB Pharma, Return on Equity, (%), 2004-2008 89
• Figure 54: DuPont Analysis for UCB Pharma, 2004-2008 89
• Figure 55: Therapeutic Focus of UCB Pharma R&D Pipeline, 2009 90
• Figure 56: R&D Productivity for UCB Pharma, 2004-2008 91
• Figure 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009 92
• Figure 58: SWOT Analysis of Genzyme 95
• Figure 59: Genzyme, Annual Revenue Forecasts, ($m), 2004-2012 97
• Figure 60: Genzyme, Net Income and R&D Expense, ($m), 2004-2008 98
• Figure 61: Genzyme, Earnings per Share, ($), 2004-2008 99
• Figure 62: Genzyme, Net Profit Margin, (%), 2004-2008 100
• Figure 63: Genzyme, Current Ratio, 2004-2008 101
• Figure 64: Genzyme, Debt to Equity Ratio, 2004-2008 102
• Figure 65: Genzyme, Return on Equity, (%), 2004-2008 103
• Figure 66: DuPont Analysis for Genzyme, 2004-2008 103
• Figure 67: Therapeutic Focus of Genzyme R&D Pipeline, 2009 104
• Figure 68: R&D Productivity for Genzyme, 2004-2008 105
• Figure 69: Phase-wise Analysis of Genzyme R&D Pipeline, 2009 106
• Figure 70: SWOT Analysis of Biogen Idec 110
• Figure 71: Biogen Idec, Annual Revenue Forecasts, ($m), 2004-2012 112
• Figure 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008 113
• Figure 73: Biogen Idec, Earnings per Share, ($), 2004-2008 114
• Figure 74: Biogen Idec, Net Profit Margin, (%), 2004-2008 115
• Figure 75: Biogen Idec, Current Ratio, 2004-2008 116
• Figure 76: Biogen Idec, Debt to Equity Ratio, 2004-2008 117
• Figure 77: Biogen Idec, Return on Equity, (%), 2004-2008 118
• Figure 78: DuPont Analysis for Biogen Idec, 2004-2008 118
• Figure 79: Therapeutic Focus of Biogen Idec R&D Pipeline, 2009 119
• Figure 80: R&D Productivity for Biogen Idec, 2004-2008 120
• Figure 81: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009 121
• Figure 82: SWOT Analysis of CSL Limited 124
• Figure 83: CSL Limited, Annual Revenue Forecasts, ($m), 2005-2013 126
• Figure 84: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009 127
• Figure 85: CSL Limited, Earnings per Share, ($), 2005-2009 128
• Figure 86: CSL Limited, Net Profit Margin, (%), 2005-2009 129
• Figure 87: CSL Limited, Current Ratio, 2005-2009 130
• Figure 88: CSL Limited, Debt to Equity Ratio, 2005-2009 131
• Figure 89: CSL Limited, Return on Equity, (%), 2005-2009 132
• Figure 90: DuPont Analysis for CSL Limited, 2005-2009 132
• Figure 91: Therapeutic Focus of CSL Limited R&D Pipeline, 2009 133
• Figure 92: R&D Productivity for CSL Limited, 2005-2009 134
• Figure 93: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009 135
• Figure 94: SWOT Analysis of Celgene 138
• Figure 95: Celgene, Annual Revenue Forecasts, ($m), 2004-2012 140
• Figure 96: Celgene, Net Income and R&D Expense, ($m), 2004-2008 141
• Figure 97: Celgene, Earnings per Share, ($), 2004-2008 142
• Figure 98: Celgene, Net Profit Margin, (%), 2004-2008 142
• Figure 99: Celgene, Current Ratio, 2004-2008 143
• Figure 100: Celgene, Debt to Equity Ratio, 2004-2008 144
• Figure 101: Celgene, Return on Equity, (%), 2004-2008 145
• Figure 102: DuPont Analysis for Celgene, 2004-2008 145
• Figure 103: Therapeutic Focus of Celgene R&D Pipeline, 2009 146
• Figure 104: R&D Productivity for Celgene, 2004-2008 147
• Figure 105: Phase-wise Analysis of Celgene R&D Pipeline, 2009 148
• Figure 106: SWOT Analysis of Cephalon 151
• Figure 107: Cephalon, Annual Revenue Forecasts, ($m), 2004-2012 153
• Figure 108: Cephalon, Net Income and R&D Expense, ($m), 2004-2008 154
• Figure 109: Cephalon, Earnings per Share, ($), 2004-2008 155
• Figure 110: Cephalon, Net Profit Margin, (%), 2004-2008 155
• Figure 111: Cephalon, Current Ratio, 2004-2008 156
• Figure 112: Cephalon, Debt to Equity Ratio, 2004-2008 157
• Figure 113: Cephalon, Return on Equity, (%), 2004-2008 158
• Figure 114: DuPont Analysis for Cephalon, 2004-2008 158
• Figure 115: Therapeutic Focus of Cephalon R&D Pipeline, 2009 159
• Figure 116: R&D Productivity for Cephalon, 2004-2008 160
• Figure 117: Phase-wise Analysis of Cephalon R&D Pipeline, 2009 161
• Figure 118: SWOT Analysis of Actelion 164
• Figure 119: Actelion, Annual Revenue Forecasts, ($m), 2004-2012 165
• Figure 120: Actelion, Net Income and R&D Expense, ($m), 2004-2008 166
• Figure 121: Actelion, Earnings per Share, ($), 2004-2008 167
• Figure 122: Actelion, Net Profit Margin, (%), 2004-2008 168
• Figure 123: Actelion, Current Ratio, 2004-2008 169
• Figure 124: Actelion, Debt to Equity Ratio, 2004-2008 170
• Figure 125: Actelion, Return on Equity, (%), 2004-2008 171
• Figure 126: DuPont Analysis for Actelion, 2004-2008 171
• Figure 127: Therapeutic Focus of Actelion R&D Pipeline, 2009 172
• Figure 128: R&D Productivity for Actelion, 2004-2008 173
• Figure 129: Phase-wise Analysis of Actelion R&D Pipeline, 2009 174
• Figure 130: Research Methodology 179

Other users found this report page using the following search terms: biotech biotech companies swot top analysis 2009 biotechnology pharma ratio company

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.